News | 13 September 2012
Mr. De Silva will remain with the Company through the remainder of the year, when the integration planning efforts related to its announced acquisition of Medicis Pharmaceutical Corporation (NYSE: MRX) are expected to have been completed. Mr. De Silva ...
Click on the link to read the full article at Stockhouse
(This link will open in a new window)